(–) -JJ-450

• Description:

  (-) -JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) . (-) -JJ-450 is more potent than (+) -JJ-450 (HY-403733B) in inhibiting androgen-induced AR activity, and the mechanism of AR inhibition by (+) -JJ-450 is different from that of Enzalutamide (MDV3100) (HY-70003), which may target the ligand binding domain (LBD) of AR. (-) -JJ-450 inhibits the transcriptional activity of wild-type AR and mutant ARF876L by inhibiting AR nuclear translocation and promoting nuclear degradation of unbound AR. (-) -JJ-450 can be used in the study of castration-resistant prostate cancer (CRPC) resistant to Enzalutamide[1].

• UNSPSC:

  12352005

• Target:

  Androgen Receptor

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  O=C([C@H]1C[C@H]1C2=CC=C(C=C2)F)N3CCN(CC3)C4=CC(Cl)=CC=C4C

• Molecular Formula:

  C21H22ClFN2O

• Molecular Weight:

  372.86

• References & Citations:

  [1]Cole RN, et al. (+) -JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist. Mol Cancer Ther. 2022 Apr 1;21 (4) :483-492.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1998094-23-7]